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Early prediction and prevention of type 1 diabetes (T1D) are currently unmet medical needs. Previous
metabolomics studies suggest that children who develop T1D are characterised by a distinct metabolic
proﬁle already detectable during infancy, prior to the onset of islet autoimmunity. However, the speciﬁcity
of persistent metabolic disturbances in relation T1D development has not yet been established. Here, we
report a longitudinal plasma lipidomics dataset from (1) 40 children who progressed to T1D during follow-
up, (2) 40 children who developed single islet autoantibody but did not develop T1D and (3) 40 matched
controls (6 time points: 3, 6, 12, 18, 24 and 36 months of age). This dataset may help other researchers in
studying age-dependent progression of islet autoimmunity and T1D as well as of the age-dependence of
lipidomic proﬁles in general. Alternatively, this dataset could more broadly used for the development of
methods for the analysis of longitudinal multivariate data.
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Measurement Type(s) lipid
Technology Type(s) liquid chromatography-tandem mass spectrometry
Factor Type(s) age • disease stage • autoantibody measurement
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Background & Summary
Type 1 diabetes (T1D) is a chronic, autoimmune disease caused by progressive loss of insulin-secreting
capacity due to the selective death of beta cells in the islets of Langerhans, of which there are more than
one million in the human pancreas1. The age of onset is usually between 5–15 years, but, in recent years,
many children before 5 years of age are being affected2. Although approximately 80% of subjects with
T1D carry deﬁned risk-associated genotypes at the human leukocyte antigen (HLA) locus, only 3–7% of
the carriers of such genetic risk markers go on to develop overt disease. Seroconversion to islet
autoantibody positivity is the ﬁrst detectable signal demonstrating initiation of autoimmunity and risk of
progression towards diabetes3,4. However, whilst seroconversion to autoantibody positivity precedes
clinical disease by months to years, the point at which seroconversion occurs may already be too late for
therapeutic approaches aimed at preventing progression to overt diabetes.
Previous metabolomic studies suggest that children who develop islet autoimmunity and/or T1D are
characterised by speciﬁc metabolic disturbances prior to the ﬁrst appearance of islet autoantibodies5–7.
Metabolic proﬁling may thus be of clinical relevance by providing a complimentary tool for estimating
risk of progression to T1D. However, the underlying causes of these early metabolic disturbances and
their link to disease progression are still largely unknown. It is also not yet established if the observed,
persistent metabolic changes are speciﬁcally associated with the progression to T1D, or more broadly, if
they are associated with progression to islet autoimmunity and irrespective of disease outcome.
Here we provide a longitudinal plasma lipidomics dataset obtained from children participating in a
prospective, birth cohort Type 1 Diabetes Prediction and Prevention study (DIPP). Three study
groups were examined: children who (1) progressed to T1D (PT1D), (2) developed at least a single
islet autoantibody (Ab) during follow-up but did not progress to T1D (P1Ab), and (3) controls (CTR)
who remained autoantibody negative and healthy during the follow-up until 15 years of age. We
analysed 428 plasma samples from 120 children (40 PT1D, 40 P1Ab and 40 CTR). The samples were
collected up to six different time points corresponding to the ages of 3, 6, 12, 18, 24, and 36 (or above)
months (Fig. 1). These age groups were selected with the objective of understanding the changes in
lipidomic proﬁle preceding prior to overt T1D. We performed untargeted lipidomics using ultra-high-
performance liquid chromatography combined with quadrupole time-of-ﬂight mass spectrometry
(UHPLC-QTOF-MS). Both raw and pre-processed datasets were deposited in the MetaboLights
repository (Data Citation 1). Along with the aforementioned lipidomic data, we provide information
on the type of islet autoantibodies observed in this longitudinal setting. In this study, sphingomyelins
(SMs) were found to be persistently downregulated in PT1D as compared to the P1Ab and CTR
groups8. Triacylglycerols (TGs) and phosphatidylcholines (PCs) were mainly downregulated in PT1D
as compared to P1Ab at the age of 3 months. These results suggest that distinct lipidomic signatures
characterise children who progressed to islet autoimmunity or clinical T1D. Lipidomic proﬁling may
thus be helpful in the identiﬁcation of at-risk children before the initiation of autoimmunity.
This data descriptor is one of the ﬁrst longitudinal lipidomic datasets allowing the investigation of
progression to islet autoimmunity/T1D during the early prodromal phases of disease development.
Considering the longitudinal study design, this clinical dataset may have many uses. Firstly, it may assist
other researchers in their studies of early pathogenesis of T1D and, potentially, other immune-mediated
inﬂammatory diseases. It may also allow other researchers to study the age-dependent progression of
lipidomic proﬁles during infancy. Finally, the dataset has great potential to be used in the development
and testing of algorithms for the analysis of multivariate longitudinal/prospective data.
Methods
These methods are expanded versions of descriptions in our related work8.
Study design
The plasma samples for lipidomics analysis were obtained from the Finnish Type 1 Diabetes Prevention
and Prediction (DIPP) study9. The DIPP study has screened more than 220,000 newborn infants
for HLA-conferred susceptibility to T1D at three university hospitals in Finland: Turku, Tampere and
Oulu10. Over 25,000 infants were identiﬁed as having an increased genetic risk and approximately 17,000
families joined the follow-up study, which involves regular study center visits (with an interval of 3–6
months). The Ethics and Research Committee of the participating Universities and Hospitals approved
the study protocol. The study was conducted according to the guidelines in the Declaration of Helsinki.
All families provided written informed consent for participation in the study. At every visit, blood
samples were collected to measure the titre of T1D-associated islet autoantibodies. Non-fasting blood
samples were collected into sodium citrate tubes. Plasma was separated within 30 min of collection by
centrifugation at 1600g for 20 min at room temperature, aliquoted, and stored at −80 °C until analysed.
Now, 1,663 of those children (9.8%) have seroconverted to positivity for one autoantibody during the
follow-up, 808 (4.8%) have developed multiple autoantibodies, and 510 (3.1%) have progressed to
clinical T1D.
The 120 infants included in the current data descriptor were selected from a subset of DIPP children
from the city of Tampere. Up to six longitudinal samples per child were collected between 1998 and 2012,
corresponding to the ages of 3, 6, 12, 18, 24 and 36 months (Fig. 1, Table 1). The details of the ages and
selected characteristics of the current study subjects are given in the metadata (Data Citation 1). The three
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study groups were matched by HLA-associated diabetes risk, gender and the period of birth. In total, 428
plasma samples were selected and analysed for this study.
HLA genotyping
HLA-conferred susceptibility to T1D was analysed using cord blood samples as previously described11.
Brieﬂy, the HLA-genotyping was performed with a time-resolved ﬂuorometry-based assay for four
alleles using lanthanide chelate labeled, sequence-speciﬁc oligonucleotide probes detecting the DQB1∗02,
DQB1∗03:01, DQB1∗03:02 and DQB1∗06:02/3 alleles12. The carriers of the genotype DQB1∗02/DQB1∗03:02
or DQB1∗03:02/x genotypes (here x ≠ DQB1∗02, DQB1∗03:01, DQB1∗06:02, or DQB1∗06:03 alleles) were
categorised into the T1D risk group and recruited for the DIPP follow-up program.
Detection of beta-cell autoimmunity
The participants with HLA-conferred genetic susceptibility were monitored for the appearance of T1D-
associated autoantibodies: islet cell antibodies (ICA), insulin autoantibodies (IAA), islet antigen 2
autoantibodies (IA-2A), and glutamic acid decarboxylase autoantibodies (GADA). These autoantibodies
were measured in the Diabetes Research Laboratory (University of Oulu) from the plasma samples taken
at each follow-up visit13. ICA were detected with the use of indirect immunoﬂuorescence, whereas the
other three autoantibodies were quantiﬁed with the use of speciﬁc radiobinding assays14. We used cutoff
limits for positivity of 2.5 Juvenile Diabetes Foundation (JDF) units for ICA, 3.48 relative units (RU)
for IAA, 5.36 RU for GADA, and 0.43 RU for IA-2A. The disease sensitivity and speciﬁcity of the
assay for ICA were 100% and 98%, respectively, in the fourth round of the international workshops on
standardisation of the ICA assay. According to the Diabetes Autoantibody standardisation Program
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Figure 1. An overview of the study design. In this study, newborn infants at the University Hospital of
Tampere were screened for increased genetic risk for T1D. This study includes three study groups: (1) 40
T1D (PT1D) progressors, (2) 40 who developed at least a single Ab during the follow-up but did not progress to
T1D (P1Ab), and (3) 40 controls (CTRL) who remained autoantibody negative during the follow-up. The three
study groups were matched by HLA-associated diabetes risk, gender and period of birth. For each child, up to
six longitudinal samples were obtained corresponding to the ages of 3, 6, 12, 18, 24 and 36 (or above) months.
Abbreviations: islet cell antibodies (ICA), insulin autoantibodies (IAA), islet antigen 2 (IA-2) autoantibodies,
and glutamic acid decarboxylase autoantibodies (GADA).
PT1D (n = 40) P1Ab (n = 40) CTR(n = 40)
Gender (girls, boys) (14, 26) (14, 26) (14, 26)
Age at time of diagnosis (years) (mean ± SD) 4.75 ± 2.94 NA NA
Age at time of ﬁrst seroconversion (years) (mean ± SD) 1.34 ± 0.58 3.05 ± 2.50 NA
Table 1. Anthropometric characteristics of study population.
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(DASP) and Islet Autoantibody standardisation Program (IASP) workshop results in 2010–2015, disease
sensitivities for the IAA, GADA and IA-2A radio binding assays were 36–62%, 64–88% and 62–72%,
respectively. The corresponding disease speciﬁcities were 94–98%, 94–99% and 93–100%, respectively.
The metadata in the Metabolights contains information on the types of autoantibodies detected in the
longitudinal plasma samples (Data Citation 1).
Sample preparation and UHPLC-MS analysis
The solvents and eluent modiﬁers used in this work were purchased from Sigma-Aldrich (Steinheim,
Germany): HPLC-grade chloroform, LC-MS grade acetonitrile (ACN), isopropanol (IPA), water (H2O),
methanol (MeOH), ammonium acetate (NH4Ac), analytical grade formic acid (HCOOH) and sodium
chloride (NaCl).
The following internal standards were purchased for quality control (QC) and calibration purposes:
1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine (PE(17:0/17:0)), N-heptadecanoyl-D-erythro-sphin-
gosylphosphorylcholine (SM(d18:1/17:0)), N-heptadecanoyl-D-erythro-sphingosine (Cer(d18:1/17:0)),
1,2-diheptadecanoyl-sn-glycero-3-phosphocholine (PC(17:0/17:0)), 1-heptadecanoyl-2-hydroxy-sn-glycero-
3-phosphocholine (LPC(17:0)) and 1-palmitoyl-d31-2-oleoyl-sn-glycero-3-phosphocholine (PC(16:0/
d31/18:1)) from Avanti Polar Lipids, Inc. (Alabaster, Alabama, USA), 1,2-Dimyristoyl-sn-glycero-3-
phospho(choline-d13) (PC(14:0/d13)) from Sigma-Aldrich and Tripalmitin-1,1,1-13C3 (TG(16:0/16:0/16:0)-
13C3) and Trioctanoin-1,1,1-13C3 (TG(8:0/8:0/8:0)-13C3) from Larodan (Solna, Sweden). Stock solutions
(1.0 mgmL−1) of the internal standards were prepared by dissolving the analytes in CHCl3:MeOH (2:1, v/v).
The working standard solutions were prepared by further diluting the stock solutions in CHCl3:MeOH (2:1,
v/v) to achieve concentrations of 250 ngmL−1 and 3.5 μgmL−1.
Calibration curves using 1-hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine (PC(16:0e/
18:1(9Z))), 1-(1Z-octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine (PC(18:0p/18:1(9Z))),
1-octadecanoyl-sn-glycero-3-phosphocholine (LPC(18:0)), 1-(1Z-octadecenyl)-2-docosahexaenoyl-sn-
glycero-3-phosphocholine (PC(18:0p/22:6)) and 1-stearoyl-2-linoleoyl-sn-glycerol (DG(18:0/20:4)) from
Avanti Polar Lipids Inc., 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphatidylcholine (LPC(16:0)) from
Larodan, and 1,2,3-Triheptadecanoylglycerol (TG(17:0/17:0/17:0)) and 3β-Hydroxy-5-cholestene
3-linoleate (ChoE(18:2)) from Sigma-Aldrich were prepared to the following concentration levels: 100,
500, 1000, 1500, 2000 and 2500 ngmL−1 (in CHCl3:MeOH, 2:1, v/v) including 250 ng mL
−1 of each QC
standard.
A total of 428 plasma samples were extracted in randomised order using a modiﬁed version of the
Folch procedure: 10 μL of 0.9% NaCl, 40 μL of CHCl3:MeOH (2:1, v/v) and 80 μL of the 3.5 μg mL−1
working standards solution were added to 10 μL of each plasma sample. The samples were vortex mixed
and incubated on ice for 30 min after which they were centrifuged (9400 × g, 3 min, 4 °C). From the
lower layer of each sample, 60 μL was transferred to a glass vial with an insert and 60 μL of CHCl3:MeOH
(2:1, v/v) and added to each sample. The samples were re-randomised and stored at 80 °C until analysis
on the UHPLC-QTOF-MS system.
The UHPLC system used was a 1290 Inﬁnity system from Agilent Technologies (Santa Clara,
California, USA). The system was equipped with a multisampler (maintained at 10 °C) using 10% DCM
in MeOH and ACN:MeOH:IPA:H2O (1:1:1:1, v/v/v/v) + 0.1% HCOOH as needle wash solutions
after each injection for 7.5 s each, a quaternary solvent manager and a column thermostat (maintained at
50 °C). Separations were performed on an ACQUITY UPLC® BEH C18 column (2.1 mm × 100 mm,
particle size 1.7 μm) by Waters (Milford, USA). The ﬂow rate was 0.4 mLmin−1 and the injection volume
was 1 μL. H2O + 1% NH4Ac (1M) + 0.1% HCOOH (A) and ACN:IPA (1:1, v/v) + 1% NH4Ac + 0.1%
HCOOH (B) were used as the mobile phases for the gradient elution. The gradient was as follows: from 0
to 2 min. 35-80% B, from 2 to 7 min. 80–100% B and from 7 to 14min 100% B. Each run was followed by
a 7 min re-equilibration period under the initial conditions (35% B).
The mass spectrometer coupled to the UHPLC was a 6550 iFunnel QTOF-MS from Agilent
Technologies interfaced with a dual jet stream electrospray (dual ESI) ion source. Nitrogen generated by a
nitrogen generator (PEAK Scientiﬁc, Scotland, UK) was used as the nebulising gas at a pressure of 21 psi,
as the drying gas at a ﬂow rate of 14 L min−1 (at 193 °C) and as the sheath gas at a ﬂow rate of 11 L min−1
(at 379 °C). Pure nitrogen (6.0) from Praxair (Fredericia, Denmark) was used as the collision gas. The
capillary voltage and the nozzle voltage were kept at 3643 V and 1500 V, respectively. The reference mass
solution including ions at m/z 121.0509 and 922.0098 was prepared according to instructions by Agilent
and was introduced to the mass spectrometer through the other nebuliser in the dual ESI ion source using
a separate Agilent series 1290 isocratic pump at a constant ﬂow rate of 4 mLmin−1 (split to 1:100 before
the nebuliser). The acquisition mass range was m/z 100–1700 and the instrument was run in extended
dynamic range mode with an approximate resolution of 30,000 FWHM measured at m/z 1521.9715
(which is included in the tune mixture) during calibration of the instrument. MassHunter B.06.01
software (Agilent) was used for data acquisition.
Data pre-processing
The data pre-processing was performed using MZmine 2.18.215. Here, we have adhered to the data
processing steps as suggested by the metabolomics standards initiative16. The typical pre-processing
workﬂow includes raw ﬁle import, ﬁltering/smoothing, detection of peaks, peak list de-isotoping,
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alignment, gap ﬁlling, integration of peaks, normalisation and, ﬁnally, peak/feature identiﬁcation (Fig. 2,
and Supplementary Table S1). The following steps were applied in the processing: (1) crop ﬁltering with a
m/z range of 350–1700 m/z and a retention time (RT) range of 2.5 to 21.0 min, (2) mass detection with a
noise level of 750, (3) chromatogram builder with a minimum time span of 0.08 min, minimum height of
2250 and a m/z tolerance of 0.006m/z or 10.0 ppm, (4) Chromatogram deconvolution using the local
minimum search algorithm with a 70% chromatographic threshold, 0.05 min minimum RT range, 5%
minimum relative height, 2250 minimum absolute height, a minimum ration of peak top/edge of 1 and a
peak duration range of 0.08 to 5.0, (5) isotopic peak grouper with a m/z tolerance of 5.0 ppm, RT
tolerance of 0.05 min, maximum charge of 2 and with the most intense isotope set as the representative
isotope, (6) peak ﬁlter with minimum 12 data points, a FWHM between 0.0 and 0.2, tailing factor
between 0.45 and 2.22 and asymmetry factor between 0.40 and 2.50, (7) peak list row ﬁlter keeping only
peak with a minimum of 1 peak in a row, (8) join aligner with a m/z tolerance of 0.006 or 10.0 ppm and a
weight for of 2, a RT tolerance of 0.1 min and a weight of 1 and with no requirement of charge state or ID
and no comparison of isotope pattern, (9) peak list row ﬁlter with a minimum of 53 peak in a row (=10%
of the samples), (10) duplicate peak ﬁlter with a m/z tolerance of 0.006 m/z or 10.0 ppm and a RT
tolerance of 0.1 min, (11) gap ﬁlling using the same RT and m/z range gap ﬁller algorithm with an m/z
tolerance of 0.006 m/z or 10.0 ppm, (12) peak ﬁlter using the same parameters as under step 6, (13) peak
list row ﬁlter with a minimum of 265 peaks in a row (=50% of the samples), enabling detection of 1084
features (14) identiﬁcation of lipids using a custom database search (232 identiﬁed out of 1084 features)
with an m/z tolerance of 0.006 m/z or 10.0 ppm and a RT tolerance of 0.1 min, (15) normalisation using
lipid-class-speciﬁc internal standards (PE (17:0/17:0), SM (d18:1/17:0), Cer (d18:1/17:0), LPC (17:0), TG
(16:0/16:0/16:0)-13C3 and PC (16:0/d30/18:1)) using in-house developed R-script, and (16) data
imputation of missing values with the half of the minimum value for each lipid.
Code availability
All the pre-processing analyses were performed using the publicly-available software package MZmine
2.18.2 and with parameters as described in Supplementary Table S1.
Data records
The raw data ﬁles in .mzML format are deposited in the MetaboLights repository (Data Citation 1).
Additionally, the deposited data contains the pre-processed lipidomic data as obtained from MZmine
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Figure 2. The typical workﬂow for processing mass spectrometry data using MZmine 2. The workﬂow
includes raw ﬁle import, ﬁltering/smoothing, detection of peaks, peak list de-isotoping, alignment, gap ﬁlling,
and integration of peaks, normalisation, and, ﬁnally, peak/feature identiﬁcation.
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data processing, including the identiﬁed lipids. The associated data were captured using the ISA-creator
package available from MetaboLights. This manuscript describes the samples, data collection, processing
steps and overall study design.
Ethical approval and informed consent
The ethics and research committees of both the participating university and hospital at University of
Tampere, Tampere Finland, approved the study protocol. The study was conducted according to the
guidelines in the Declaration of Helsinki. All families provided written informed consent for participation
in the study.
Technical validation
This study followed the best practices of analytical methodologies for the global proﬁling of lipids in
the plasma sample as described by Hyotylainen et al.17,18. For quality monitoring, QC samples (pooled
plasma samples), blank samples, pure standards (standards in solvent) were run at regular intervals
after every 4–16 study samples. To assure data quality, relative standard deviations (%RSDs) were
calculated for the retention times and the peak areas for each QC standard in the QC samples
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Figure 3. Quality control of UHPLC-QTOFMS run evaluated using peak areas from nine internal
standard compounds. (a) Plot of peak areas with 430 samples. (b) Plot of peak areas of 428 samples, i.e. after
removal of 2 outlier samples. Here, each color represents the peak area of the given internal standard PE
(17:0/17:0), SM(d18:1/17:0), Cer (d18:1/17:0), PC(17:0/17:0), LPC(17:0), PC(14:0/d13), TG(16:0/16:0/16:0)-
13C3, TG(8:0/8:0/8:0)-13C3 and PC(16:0/d31/18:1).
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throughout the sample set. Overall, these results show a reproducible method. For example, pooled
plasma samples analysed throughout the sample set show average %RSDs for the four batches of
samples of less than 0.2 and 15.4% (normalised using PC(16:0/d30/18:1)) for the retention times and
peak areas, respectively. The %RSDs for the rest of the QC samples were in the same range as for the
pooled plasma samples.
To assess experimental error, nine internal standards were spiked into the plasma samples during sample
preparation. The plot of peak areas from nine QC standards (Fig. 3a) clearly shows that two samples had
eccentric internal standard proﬁles. This was traced to an error during sample preparation, wherein the QC
standard was added two these two samples twice. Therefore, these two outlier samples were not included in
downstream analysis (and not included in the data descriptor). The representative quality plots after
removal of aberrant samples (Fig. 3b) demonstrates that the peak areas of the QC standards have very low
variability between the measured samples. This indicates that use of proper internal standards and careful
follow-up of the response of these internal standards critically reduces the chances of unexpected variation,
which may arise in LC-MS analysis. Based on this, we conclude that the samples in this data descriptor were
successfully analysed following generally accepted analytical quality guidelines.
During LC-MS analyses, it is also highly important to keep track of blank samples inserted into the
sample sequence. This is done to detect possible contamination/interference, which affect the actual
sample data. We analysed 293 blank or solvent blank samples throughout this sample set. Solvent
blank samples (consisting of a mixture of CHCl3: MeOH, 2:1, v/v) were analysed after every 4
th sample and
blank samples (the same solvent mixture, which underwent the normal sample preparation procedure
except for the addition of internal standards) after every 16th sample. Additionally, a set of QC samples (186
samples) were analysed at the same frequency as the blank samples (i.e. after every 16th sample). This set of
QC samples consisted of: (1) extracted and non-extracted standard samples (the chosen QC standards in
solvent), (2) a pooled plasma sample originating from a larger plasma pool from actual diabetes
patients for following up on long-term method performance and to facilitate batch correction if needed, and
(3) a Standard Reference Material 1950 sample from the National Institute of Standards and Technology
(NIST) that serve as community-wide benchmarks for intra- and inter-laboratory QC and method
validation19.
Next, for quantitative analysis, calibration curves of each analyte must be generated. For global
lipidomics analyses this is, however, logistically and practically impossible due to the high number of
analytes present in the biological sample matrix. To overcome this limitation, lipid-class-speciﬁc
compounds were used for creating a semi-quantitative method including six different concentrations
of the lipid class speciﬁc standards PC (16:0e/18:1(9Z)), TG (17:0/17:0/17:0), LPC (18:0), DG
(18:0/20:4) and CE (18:2). The acceptance of LC-MS data usually relies on QC samples being
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Figure 4. Representative global linear models. Six different concentrations of lipid class-speciﬁc standards
TG (17:0/17:0/17:0), and LPC (16:0) were used to generate the calibration plot.
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successfully quantiﬁed within pre-deﬁned limits. Achievement of this standard is evaluated
statistically (global linear models) based on the value for the coefﬁcient of determination (R2).
Figure 4 shows coefﬁcients of determination higher than 0.9 for TG (17:0/17:0/17:0) and LPC(16:0) at
six different concentrations using a global linear model with a 1/x weighting. The other standards
show similar values (i.e. R2 > 0.9). This statistical analysis consequently ensured the reliability of
results presented in this data descriptor.
Furthermore, the assurances provided by the QC methods herein derive from analytical
reproducibility, within or between batches of the LC-MS data. These inter- and intra-batch variations
can be assessed and corrected using the QC samples. The principal component analysis (PCA) score plot
(Supplementary Figure S1) highlights the aforementioned reproducibility across all batches obtained
from the pre-processed dataset in this data descriptor. From this score plot, it is apparent that there are
no patterns or any clustering that correlated with the batch run during LC-MS. Together, the dataset in
this data descriptor reﬂects robustness of lipid measurement over time, which, in turn, indicates that data
analysis performed using this dataset will not be affected by systematic error arising due to instrumental
factors.
Usage notes
The pre-processed data are available from MetaboLights (Data Citation 1). The detail parameters for
data pre-processing are available in supplementary material (Supplementary Table S1). The pre-
processed data were normalised using the nine different class-speciﬁc internal standards. The class-
speciﬁc were based on PE (17:0/17:0), SM (d18:1/17:0), Cer (d18:1/17:0), LPC (17:0), TG
(16:0/16:0/16:0)-13C3 and PC (16:0/d30/18:1), while others were based on retention time; LPC
(17:0) for o = 6.0 min elutions, PC(16:0/d30/18:1) for >6.0, o9.0 min elutions and TG(16:0/16:0-
/16:0)-13C3 for > = 9.0 min elutions. In addition, the zero values in the lipidomics dataset were
imputed with half of that row’s minimum value for each lipid (the code for this imputation were
written in-house using R, and are available on request). Due to the non-normal distribution of data, it
is recommended that the data are log-transformed before analysis (log-transformation performed in
MZmine 2.18.2). Other required guidelines for data-preprocessing are available from the MZmine
website (http://mzmine.github.io/documentation.html) and authors can be contacted for further help
if required.
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